PIPAC

Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC): A Minimally Invasive Breakthrough in Cancer Treatment

Peritoneal metastasis remains a challenging condition in oncology, often associated with limited therapeutic options and poor prognosis. Traditional systemic chemotherapy and surgical interventions show restricted efficacy due to drug resistance, toxicity, and limited drug penetration into the peritoneal cavity. Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) has emerged as an innovative, minimally invasive technique that enhances local drug delivery, offering hope for patients with advanced abdominal cancers.

What is PIPAC?

PIPAC is a novel drug delivery method designed to treat peritoneal surface malignancies such as gastric, ovarian, and colorectal cancers. Unlike conventional intraperitoneal chemotherapy, which administers liquid drugs, PIPAC utilizes a laparoscopic approach to nebulize chemotherapy into a fine aerosol under pressure. This technique increases drug distribution, penetration, and effectiveness while minimizing systemic side effects.

How PIPAC Works

  1. Minimally Invasive Access: Surgeons perform laparoscopy to access the abdominal cavity.

  2. Aerosolization of Chemotherapy: A special device converts liquid chemotherapy into a pressurized aerosol.

  3. Controlled Pressure Delivery: The aerosol is distributed homogeneously within the peritoneum under controlled pressure.

  4. Improved Absorption: Pressurization enhances tissue penetration, leading to higher local drug concentration and better therapeutic response.

  5. Repeatability: PIPAC can be administered multiple times as part of palliative or combination therapy.

Indications of PIPAC

PIPAC is particularly considered for patients with:

  • Peritoneal metastasis from gastric, ovarian, colorectal, and appendiceal cancers

  • Chemotherapy-resistant peritoneal carcinomatosis

  • Recurrent disease unsuitable for cytoreductive surgery (CRS) and HIPEC

  • Patients needing a palliative approach with reduced toxicity

Benefits of PIPAC

  • Enhanced Drug Penetration: Pressurized aerosol increases chemotherapy depth in peritoneal tissues.

  • Lower Systemic Toxicity: Reduced drug exposure to the bloodstream compared to systemic chemotherapy.

  • Repeatable Procedure: Can be safely performed multiple times for disease control.

  • Improved Quality of Life: Minimally invasive approach leads to shorter recovery times.

  • Synergy with Other Therapies: Can be combined with systemic chemotherapy or considered prior to CRS and HIPEC.

Limitations and Challenges

While PIPAC is promising, certain limitations must be recognized:

  • Not Curative Alone: Primarily used for palliative or disease-controlling purposes.

  • Limited Availability: Still restricted to specialized centers worldwide.

  • Procedure Risks: Includes anesthesia-related complications, infection, or peritoneal adhesions.

  • Ongoing Research: Long-term survival benefits are still under clinical investigation.

Future Perspectives

Ongoing clinical trials continue to refine the role of PIPAC in oncology. Research focuses on:

  • Optimizing drug formulations and dosages

  • Expanding indications to other cancers with peritoneal involvement

  • Combining PIPAC with immunotherapy and targeted agents

  • Establishing standardized protocols for widespread adoption

Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) represents a significant advancement in the management of peritoneal metastasis. By leveraging minimally invasive techniques, targeted delivery, and enhanced drug penetration, PIPAC offers improved treatment outcomes with fewer systemic side effects. Although not a stand-alone curative therapy, it serves as a valuable addition to multimodal cancer care, bridging the gap between palliation and improved survival. As research evolves, PIPAC is likely to become an essential component of future peritoneal oncology strategies.